Roberta J Weiss

US Patent:

20200181252, Jun 11, 2020

Filed:

Feb 7, 2020

Appl. No.:

16/784621

Inventors:

- Hamilton, BM
Joachim KEMPENI - Neustadt, DE
Roberta WEISS - Wynnewood PA, US

International Classification:

C07K 16/24
A61K 31/519
A61K 9/00
A61K 39/395

Abstract:

Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

US Patent:

20160280777, Sep 29, 2016

Filed:

Jun 10, 2016

Appl. No.:

15/179803

Inventors:

- Hamilton, BM
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US

International Classification:

C07K 16/24
A61K 31/519
A61K 9/00
A61K 39/395

Abstract:

Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

US Patent:

20150246968, Sep 3, 2015

Filed:

May 18, 2015

Appl. No.:

14/715310

Inventors:

- Hamilton, BM
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US

International Classification:

C07K 16/24
A61K 39/395
A61K 31/519

Abstract:

Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

US Patent:

20150175691, Jun 25, 2015

Filed:

Feb 27, 2015

Appl. No.:

14/634478

Inventors:

- Hamilton, BM
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US

International Classification:

C07K 16/24
A61K 39/395
A61K 31/519

Abstract:

Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

US Patent:

20150165023, Jun 18, 2015

Filed:

Feb 27, 2015

Appl. No.:

14/634530

Inventors:

- Hamilton, BM
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US

International Classification:

A61K 39/395
A61K 31/519

Abstract:

Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

US Patent:

20150079101, Mar 19, 2015

Filed:

Nov 14, 2014

Appl. No.:

14/542505

Inventors:

- Hamilton, BM
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US

International Classification:

C07K 16/24

US Classification:

4241421

Abstract:

Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

US Patent:

20150071939, Mar 12, 2015

Filed:

Nov 14, 2014

Appl. No.:

14/542529

Inventors:

- Hamilton, BM
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US

International Classification:

C07K 16/24

US Classification:

4241421

Abstract:

Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

US Patent:

20150071945, Mar 12, 2015

Filed:

Nov 14, 2014

Appl. No.:

14/542517

Inventors:

- Hamilton, BM
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US

International Classification:

C07K 16/24

US Classification:

4241581

Abstract:

Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.